Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baichuan Jiangya is a Traditional Chinese Medicine (TCM) formulation developed by researchers at Xi'an Jiaotong University for the management of hypertension. The product is typically composed of several herbal extracts, most notably *Apocynum venetum* (Luo Bu Ma), *Uncaria rhynchophylla* (Gou Teng), and *Prunella vulgaris* (Xia Ku Cao). Its mechanism of action is multi-factorial, involving the inhibition of calcium channels (primarily via rhynchophylline from *Uncaria*), diuretic effects, and the potential modulation of the renin-angiotensin-aldosterone system (RAAS). It is primarily used in China for patients with mild to moderate essential hypertension, often categorized in TCM as liver-yang hyperactivity. While it is frequently marketed as a health supplement or nutraceutical, its formulation was developed through academic research and clinical observation at Xi'an Jiaotong University.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Baichuan Jiangya.